The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation

Canadian Journal of Urology

Volumn 20, Issue 2, 2013, Pages 6682-6689

  Garfield, Susan S ^a   Gavaghan, Meghan B ^a   Armstrong, Shannon O ^a   Jones, J Stephen ^b  

^a GfK Bridgehead   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bladder cancer; Bladder cancer detection; Cost effectiveness; Cystectomy; Cystoscopy; Cysview; Outcomes; Transurethral resection of the bladder; Utility; White light cystoscopy

Indexed keywords

5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

AGED; ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; CYSTOSCOPY; ECONOMICS; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; RETROSPECTIVE STUDY; UNITED STATES;

AGED; AMINOLEVULINIC ACID; COST-BENEFIT ANALYSIS; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES; SOFTWARE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84888269844     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. National Cancer Institute. SEER Data on Cancer of the Urinary Bladder 2005-2009. Available from: http://seer.cancer.gov/statfacts/html/urinb.html. Accessed September 24th, 2012.
2. Cysview Prescribing data from the FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022555s000lbl.pdf. Accessed September 30th, 2012.
3. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer. Can J Urol 2012;19(2):6227-6231.
4. Stenzl A, Burger M, Fradet Y et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184(5):1907-1914.
5. Grossman HB, Gomella L, Fradet Y et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178(1):62-67.
6. Lapini A, Minervini A, Masala A et al. Comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc 2012;26(12):3634-3641.
7. Malmström PU, Grabe M, Haug ES et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Scand J Urol Nephrol 2012;46(2):108-116.
8. Grossman HB, Stenzl A, Fradet Y et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188(1):58-62.
9. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003;30(4):765-766.
10. Haddix AC, Schaffer PA. Cost-effectiveness analysis. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. New York: Oxford University Press; 1996:103-129.
11. Petitti DB. Advanced Cost-Effectiveness Analyses. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. Petitti DB. New York: Oxford University Press; 1994:182-202.
12. TreeAge Software Publications. Available from: http://server. treeage.com/treeagepro/tools/resources.asp?reftype=4&w=750&h=500. Accessed September 30th, 2012.
13. Medicare Physician Fee Schedule, 2011. Available from: https://www.cms.gov/physicianfeesched/. Accessed December 13th, 2011.
14. Medicare In-Patient Prospective Payment System - DRG National Average Weights, 2011. Available from: https://www.cms.gov/acuteinpatientpps/ipps2011/itemdetail. asp?itemid=CMS1237932. Accessed December 13th, 2011.
15. Medicare Clinical Laboratory Fee Schedule, 2011. Available from: https://www.cms.gov/clinicallabfeesched/02_clinlab. asp. Accessed December 13th, 2011.
16. Kulkarni GS, Alibhai SMH, Finelli A et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus calmette-guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 2009;115(23):5450-5459.
17. Lerner SP. A phase I/II trial of transurethral surgery combined with concurrent cisplatin 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer: editorial comment. J Urol 1998(5);160:1677.
18. Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174(3):862-866.
19. Botteman MF, Pashos CL, Redalli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21(18):1315-1330.
20. Malmström PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009;43(3):192-198.
21. Leaf A. Cost effectiveness as a criterion for Medicare coverage. N Engl J Med 1989;321(13):898-900.
22. Min DeParle N-A, Shalala DE. Medicare program; criteria for making coverage decisions. Fed Register 2000;65:31124.